1263045-16-4 Usage
Uses
Used in Bioconjugation:
Mal-Amido-PEG4-acid is used as a bioconjugation agent for the attachment of biomolecules with thiol groups to other molecules or surfaces. The maleimide group provides a selective and stable linkage, while the PEG spacer improves solubility and reduces immunogenicity or non-specific interactions.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Mal-Amido-PEG4-acid is used as a component in drug delivery systems to improve the solubility, stability, and targeted delivery of therapeutic agents. The PEG spacer can enhance the bioavailability and circulation time of drugs, while the terminal carboxylic acid allows for the attachment of drug molecules or targeting ligands through amide bond formation.
Used in Diagnostics and Imaging:
In the field of diagnostics and imaging, Mal-Amido-PEG4-acid is used for the conjugation of imaging agents or contrast agents to biomolecules, enabling the development of targeted imaging probes. The stable linkage provided by the maleimide group ensures the integrity of the imaging probe, while the PEG spacer can improve its pharmacokinetics and reduce clearance rates.
Used in Biosensors and Assays:
Mal-Amido-PEG4-acid is utilized in the development of biosensors and assays, where it serves as a linker between the sensing element and the target biomolecule. The maleimide group allows for the covalent attachment of thiol-modified biomolecules, while the PEG spacer can provide a hydrophilic environment and reduce steric hindrance, enhancing the performance of the biosensor or assay.
Check Digit Verification of cas no
The CAS Registry Mumber 1263045-16-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,3,0,4 and 5 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1263045-16:
(9*1)+(8*2)+(7*6)+(6*3)+(5*0)+(4*4)+(3*5)+(2*1)+(1*6)=124
124 % 10 = 4
So 1263045-16-4 is a valid CAS Registry Number.
1263045-16-4Relevant articles and documents
Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof
-
Page/Page column 133; 134; 137; 138, (2019/11/11)
Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.
ANTI-FOLATE RECEPTOR APLHA (FRA) ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF
-
, (2016/06/28)
The present disclosure provides anti-folate receptor alpha (FRA) antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.
ANTI-CD22 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF
-
Paragraph 0273; 0281, (2016/05/09)
The present disclosure provides anti-CD22 antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.
HYDROPHILIC SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF
-
Paragraph 240; 248, (2014/07/08)
The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.
